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Abstract: The coexistence of mesothelioma and other primary malignancies has been previously reported in litera-
ture, but the finding of a pleural mesothelioma with a synchronous peritoneal mesothelioma has not been reported 
so far. We report a case of a 58-years-old woman that came to our attention for the incidental finding of an inguinal 
mass. Fine-needle biopsies of the mass and a thoracoscopy with pleural biopsies were performed, after imaging 
studies showed pleural thickenings suspicious for malignancy. Histological morphology and growth pattern were 
similar in both cases. Both tumors stained for calretinin, but only the pleural mesothelioma showed positivity for 
Wilms-Tumor 1 antibody. We tried to demonstrate with molecular biology techniques whether they were synchro-
nous or one was the metastasis of the other, but our studies did not give informative results. The prognosis in this 
case is poor, and after 6 months the patient is still following a chemotherapy regimen, which is the only practicable 
approach given the extent of the disease.
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Introduction
Malignant mesothelioma is a rare neoplasm 
that develops from mesothelial cells of the 
serosal membranes, in particular pleura (75%), 
peritoneum (10-20%), pericardium (1%) or tuni-
ca vaginalis (1%). Mesothelioma is primarily a 
disease of adults and usually arises in the fifth 
to seventh decades, and 70-80% of cases 
occur in men. Worldwide, the main cause iden-
tified in pathogenesis of malignant mesothelio-
ma is asbestos exposure. Unlike lung cancer, 
there seems to be no association between 
mesothelioma and tobacco smoking, but smok-
ing greatly increases the risk of other asbestos-
induced cancers. Signs and symptoms of pleu-
ral mesothelioma include shortness of breath 
due to pleural effusion, chest wall pain, and 
constitutional signs such as unexplained weight 
loss. Peritoneal mesothelioma usually presents 
with abdominal pain, nausea, vomiting, ascites 
and a more rapid weight loss. Medical examina-
tion can show the presence of an abdominal 
solid mass. The diagnosis may be suspected on 
chest X-ray and computerized tomography (CT) 
scan findings, but must be confirmed either by 
examining serous effusion cytology or with a 
biopsy. There are three histological types of 
malignant mesothelioma. Epithelioid mesothe-
lioma is composed of epithelioid cells with 
large, eosinophilic cytoplasm arranged in glan-
dular or pseudoacinar structures. Sarcomatoid 
histotype is characterized by the presence of 
markedly atypical spindle cells, in a storiform 
pattern, which forms whorls or beams. Biphasic 
(mixed) mesothelioma usually shows both epi-
thelioid and sarcomatoid components. Meso- 
thelioma usually carries a poor prognosis: over-
all survival is 50% at two years and 20% at five 
years. Young age at diagnosis, a good perfor-
mance status and the absence of weight loss 
are predictive of a more favorable outcome. The 
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histological subtype is also correlated with 
prognosis: epithelioid mesothelioma usually 
carries a better prognosis than the sarcoma-
toid or mixed histotype [1, 2]. The coexistence 
of mesothelioma and other primary malignan-
cies has been previously reported in literature, 
but the finding of a pleural mesothelioma with a 
synchronous peritoneal mesothelioma has not 
been reported so far [3-11].
We report a case of 58 years old woman with a 
radiological and histological diagnosis of pleu-
ral and peritoneal mesothelioma. We tried to 
demonstrate with molecular biology techniques 
whether they were synchronous or one was the 
metastasis of the other.
Case presentation
A 58-years-old non-smoker Caucasian female 
patient came to our attention for the incidental 
finding of a 2 cm inguinal mass. Clinical anam-
nesis revealed asbestos exposure during child-
hood. A positron emission tomography (PET) - 
computed tomography (CT) scan highlighted a 
large area of increased fixation of radiolabeled 
glucose in the right hemithorax. This area 
involved mainly the upper lung affecting the 
anterior, posterior, lateral and mediastinal pleu-
ra. A second area of increased fixation was also 
projected on the soft tissues of the right ingui-
nal region. She underwent a fine-needle biopsy 
of the inguinal mass and thoracoscopy with 
pleural biopsies. Written informed consent was 
obtained from the patient for this study.
The samples were paraffin-embedded and 
2-μm thick slides were stained with H&E. 
Immunohistochemistry according to standard 
protocols was performed on the most repre-
sentative blocks of the lesions. The follow- 
ing antibodies were used: Calretinin (5A5, 
Novocastra, dilution 1:100) and Wilms Tumor-1 
(6F-H2, Dako, dilution 1:50).
Figure 1. Pleural mesothelioma, showing papillary and solid growth pattern with soft tissue infiltration (A: H&E, ×40; 
B: H&E, ×100). Calretinin (C: ×400) and WT1 (D: ×400) stained the whole tumor.
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Molecular analyses
Genomic DNA was extracted from peripheral 
blood (PBL) and formalin fixed paraffin embed-
ded (FFPE), tumor samples, using the QiAmp 
MiniKit (Qiagen) and the QIAamp DNA FFPE 
Tissue Kit (Qiagen), respectively. The X-chromo- 
some inactivation (XCI) pattern was evaluated 
by the amplification (polymerase chain reac-
tion) and capillary electrophoresis of the highly 
polymorphic short tandem repeat HUMARA 
(Androgen Receptor - AR - locus, Xq11.2-q12), 
flanked by methylation-sensitive restriction 
sites. The HUMARA assay [12] was performed 
on both PBL and tumor samples. FFPE sam-
ples, PCR was performed before and after 
enzymatic digestions of the methylation sensi-
tive restriction sites, using the HpaII and HhaI 
enzymes (Boehringer Ingelheim, Mannheim, 
Germany) as previously reported [12]. All sam-
ples were tested in duplicate and one male 
DNA sample was included in the experiment as 
control for enzymatic digestion. XCI pattern was 
determined by the analysis of peak size result-
ing from capillary electrophoresis. Mutations of 
EGFR gene (exons 18, 19, 21) were investigat-
ed by means of pyrosequencing analysis using 
CE-IVD kit EGFR TKI response® (sensitivity) 
(Diatech Pharmacogenetics, Italy). Briefly, 
50-100 ng of DNA were amplified using Rotor-
Gene 6000 Q (Corbett Research, Australia) and 
20 μl of each PCR product were analyzed by 
pyrosequencing using PyroMark Q96 ID instru-
ment and Gold Q96 reagents (Qiagen), in accor-
dance with the manufacturer’s instructions. 
The sequences were analyzed with PyroMark 
ID 1.0 software (Qiagen) according to the com-
mercial kit handbooks.
Results
Histological slides of both samples showed a 
papillary and pseudoacinar malignant prolifera-
tion, with marked cytologic atypia with abun-
Figure 2. Peritoneal mesothelioma, also showing papillary and solid growth pattern with soft tissue infiltration (A: 
H&E, ×40; B: H&E, ×100). Immunohistochemistry for Calretinin (C: ×400) showed a strong positivity, but WT-1 (D: 
×400) did not stain any tumoral cell.
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dant and eosinophilic cytoplasm and with the 
invasion of the deep soft tissues. A spindle cell 
component was not identified, so a biphasic 
mesothelioma was excluded. Immunohistoche- 
mically, both the neoplasms showed reactivity 
for Calretinin; only the pleural mesothelioma 
showed immunoreactivity for Wilms Tumor-1 
(Figures 1 and 2).
In order to understand whether the two neo-
plasms were independent primaries or one the 
metastasis of the other, we performed 
X-chromosome inactivation pattern and we 
investigated mutations of the EGFR gene. As 
depicted in Figure 3, the analysis of DNA 
extracted from PBL indicated that patient was 
heterozygous at the AR locus. The evaluation of 
XCI of pleural mesothelioma and peritoneal 
mesothelioma after enzymatic digestion re- 
vealed the same profile in both samples, thus 
indicating that in both tumors the same X chro-
mosome was inactivated. Pyrosequencing 
analyses of the two mesotheliomas identified a 
wild-type pattern of EGFR gene in both sam 
ples.
Discussion
The finding of synchronous pleural malignant 
mesothelioma and peritoneal mesothelioma 
has never been described in the literature. As 
showed in Table 1, pleural mesotheliomas have 
been described mainly in association with lung 
cancer although Bianchi et al showed in a large 
series [10] an association with prostatic, renal 
and bladder carcinomas, and hematologic 
malignancies.
The simultaneous presence of two mesothelio-
mas has been identified only in the tunica vagi-
nalis of the testis, bilaterally [9]. Only one case 
of pleural mesothelioma metastatic to an ingui-
nal lymph node was described [4], but in our 
case the tissue from the inguinal mass did not 
show nodal parenchyma.
Given the monoclonal origin of tumors, it was 
conceivable that two different tumors were 
characterized by a different molecular pattern 
of XCI and/or a different spectrum of EGFR 
mutation. The finding of molecular differences 
between pleural mesothelioma and peritoneal 
mesothelioma would have allowed us to dem-
onstrate a different origin of the two tumors. In 
investigated samples, the same molecular pro-
file was found, which could indicate the same 
origin of the two tumors or could be a stochas-
Figure 3. Allelic profile of PBL (top), pleural (middle) 
and peritoneal (bottom) with the corresponding al-
lele sizing are depicted.
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Table 1. Pleural, peritoneal and tunica vaginalis mesotheliomas 
in association with other malignancies published in literature
Case # Sex Age Tumor 1 Tumor 2
1 [3] F 55 pleural Lung, adenocarcinoma
2 M 62 pleural Lung, adenocarcinoma
3 M 72 pleural Lung, adenocarcinoma
4 M 64 pleural Lung, adenocarcinoma
5 M 71 pleural Lung, adenocarcinoma
6 n/d n/d pleural Lung, adenocarcinoma
7 n/d n/d pleural Lung, adenosquamous
8 n/d n/d pleural Lung, small cell
9 [4] M 36 Pleural Inguinal lymph node metastasis
10 [5] M 62 Pleural Lung, adenocarcinoma
11 M 62 Pleural Lung, adenocarcinoma
12 M 73 Pleural Lung, adenocarcinoma
13 M 64 Pleural Lung, squamous cell
14 M 70 Pleural Lung, squamous cell
15 M 72 Pleural Lung, small cell
16 M 60 Pleural Pancreas, adenocarcinoma
17 M 75 Pleural Colon, adenocarcinoma
18 F 75 Pleural Breast, adenocarcinoma
19 [6] M 21 Tunica vaginalis Tunica vaginalis, contralateral
20 [7] n/d n/d Peritoneum Colorectal, adenocarcinoma
21 [8] n/d n/d Pleural Stomach, adenocarcinoma; bladder, TCC; 
peritoneum, metastatic mesothelioma
22 [9] M n/d Tunica vaginalis Tunica vaginalis, contralateral
23 [10] n/d n/d Pleural Prostate, adenocarcinoma
24 n/d n/d Pleural Prostate, adenocarcinoma
25 n/d n/d Pleural Prostate, adenocarcinoma
26 n/d n/d Pleural Prostate, adenocarcinoma
27 n/d n/d Pleural Prostate, adenocarcinoma
28 n/d n/d Pleural Prostate, adenocarcinoma
29 n/d n/d Pleural Prostate, adenocarcinoma
30 n/d n/d Pleural CLL
31 n/d n/d Pleural CLL
32 n/d n/d Pleural CLL
33 n/d n/d Pleural CLL
34 n/d n/d Pleural CLL
35 n/d n/d Pleural Bladder, TCC
36 n/d n/d Pleural Bladder, TCC
37 n/d n/d Pleural Bladder, TCC
38 n/d n/d Pleural Bladder, TCC
39 n/d n/d Pleural Kidney, carcinoma
40 n/d n/d Pleural Kidney, carcinoma
41 n/d n/d Pleural Kidney, carcinoma
42 n/d n/d Pleural Kidney, carcinoma
43 n/d n/d Pleural Colon, adenocarcinoma
44 n/d n/d Pleural Colon, adenocarcinoma
45 n/d n/d Pleural Colon, adenocarcinoma
46 n/d n/d Pleural Colon, adenocarcinoma
47 n/d n/d Pleural Liver, carcinoma
48 n/d n/d Pleural Liver, carcinoma
49 n/d n/d Pleural Liver, carcinoma
50 n/d n/d Pleural Liver, carcinoma
51 [11] M 72 Pleural Lung, carcinoid and B-cell lymphoma
tic event. For this reason, the 
analyses did not give informative 
results.
Even in this case, the associa-
tion with asbestos exposure has 
been highlighted by clinical ana- 
mnesis.
Asbestos fibers can deposit in 
the lung parenchyma and pene-
trate the visceral pleura, reach-
ing the pleural surface and lead-
ing to the development of mali- 
gnant mesothelial plaques. 
The pathogenesis of peritoneal 
mesothelioma remains still un- 
known, although it has been pro-
posed that asbestos fibers from 
the lung can be transported to 
the peritoneum and abdominal 
organs via the lymphatic system. 
Asbestos fibers, moreover, can 
be deposited in the gut after 
ingestion of sputum contaminat-
ed with asbestos fibers.
The clinical presentation of our 
case is peculiar because the 
patient, although affected by a 
pleural mesothelioma, present-
ed to our observation for an 
inguinal mass without complain-
ing any symptoms referable to 
the chest disease. The progno-
sis in this case is poor, according 
to the data related to the thorac-
ic and abdominal disease sepa-
rately; after 6 months of follow-
up the patient is still alive and is 
following a chemotherapy regi-
men, which is the only practica-
ble approach given the extent of 
disease.
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